Skip to main content

Alzamend Neuro, Inc.

corporate_fare Company Profile

Alzamend Neuro, Inc.

ALZN·NASDAQ·Life Sciences·CIK 0001677077

Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company that develops new products to treat Alzheimer's disease, bipolar disorder (BD), major depressive disorder (MDD), and post-traumatic stress disorder (PTSD). The company has two product candidates and aims to bring treatments or potential cures to market. Alzheimer's disease is a primary focus, affecting approximately 7.4 million Americans, a number projected to increase to 13 million individuals by 2050. It is the fifth leading cause of death in the U.S. as of 2024. Current Alzheimer's treatments offer temporary symptom relief, and while one treatment has shown to slow disease progression, none have been shown to halt it. The disease also impacts over 13 million Americans who provide an estimated 19 billion hours of unpaid care annually. In 2026, the estimated healthcare costs for treating individuals with Alzheimer's in the U.S. are expected to be $409 billion, including $263 billion in Medicare and Medicaid payments. These costs could reach $1 trillion per year by 2050 if no permanent treatment or cure is discovered.

Alzamend Neuro, Inc. (NASDAQ:ALZN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 18 items for ALZN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-17, rated 8/10. Across its 18 most recent items scored 7 or higher, the top rating is 9/10, with 17 rated 8 or above. Recent SEC coverage for ALZN spans S-3, 8-K, 8-K/A, 10-Q.

Recent high-impact activity:

  • Alzamend Registers 39.4M Ault Lending Resale Shares — 8x Current Share Count
  • FDA Rejects AL001 Bipolar Trial Design; MGH Terminates BD Study Work
  • Alzamend Cuts Ault Lending Preferred Deal to $10M, Adds Ratchet and Registration Penalties
  • Alzamend Neuro 10-Q: $7.6M Cash, Going Concern Warning, Material Weakness Persists
  • Stockholder Vote Looms for Alzamend Neuro's $25M Preferred Conversion as Nasdaq Deadlines Approach

Financial Snapshot

Fiscal year ended April 30, 2026
Net Income
-$8.77M
Diluted EPS
-$2.63
Op. Cash Flow
-$8.07M
Operating Income
-$8.77M
Cash & Equivalents
$710.69K
Debt / Equity
0.00×
Shares Outstanding
4.26M sh
Source: 10-K · filed 2026-07-22 · accession 0001214659-26-008832

Short Interest & Short Volume

1.05 days to cover

FINRA reported short interest of 17,574 shares in ALZN as of the October 30, 2026 settlement, a 48.6% decrease from the prior period — about 1.1 days to cover at its recent average daily volume. On November 20, 2026, 9.7% of ALZN volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)17,574 shares as of October 30, 2026
Change vs prior period▼ 48.6%
Days to cover1.05 at avg daily volume of 16,714
Daily short volume (FINRA facilities)9.7% of 48,912 shares on November 20, 2026
5-day average short volume11.0%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Moderate risk

Filing-implied dilution signals for ALZN, detected from its recent SEC filings · based on capital-structure filings through 2026-08-28.

2 shelf registrations

Stockholder Vote on $25M Preferred Conversion · Deeply Dilutive Conversion Formula

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with A →
$0.79 +1.83% today
52-week range · as of 2026-11-17 $0.79 – $2.56
Market cap
$3.74M
Volume
93.3K (2.5× avg)
3-mo avg 37.3K
Live data · 2026-11-21 04:35 UTC · Market overnight

show_chartPrice Chart

Loading chart...

feed ALZN - Latest Insights

ALZN
Nov 17, 2026, 5:05 PM EST
Filing Type: S-3
Importance Score:
8
Price at Filing: $1.11
Real-time Price: $0.790 info
Change: -$0.320 (-29%) info
Market Cap: $3.744M info
ALZN
Nov 17, 2026, 4:30 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.11
Real-time Price: $0.790 info
Change: -$0.320 (-29%) info
Market Cap: $3.744M info
ALZN
Nov 10, 2026, 4:30 PM EST
Filing Type: 8-K/A
Importance Score:
7
Price at Filing: $1.35
Real-time Price: $0.790 info
Change: -$0.560 (-41%) info
Market Cap: $3.744M info
ALZN
Sep 10, 2026, 4:30 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.70
Real-time Price: $0.790 info
Change: -$0.910 (-54%) info
Market Cap: $3.744M info
ALZN
Aug 28, 2026, 4:30 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $1.66
Real-time Price: $0.790 info
Change: -$0.870 (-52%) info
Market Cap: $3.744M info
ALZN
Aug 21, 2026, 4:30 PM EDT
Filing Type: S-1
Importance Score:
8
Price at Filing: $1.50
Real-time Price: $0.790 info
Change: -$0.710 (-47%) info
Market Cap: $3.744M info
ALZN
Aug 03, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.35
Real-time Price: $0.790 info
Change: -$0.560 (-41%) info
Market Cap: $3.744M info
ALZN
Jul 22, 2026, 4:30 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $1.35
Real-time Price: $0.790 info
Change: -$0.560 (-41%) info
Market Cap: $3.744M info
ALZN
Apr 17, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.13
Real-time Price: $0.790 info
Change: -$0.3395 (-30%) info
Market Cap: $3.744M info
ALZN
Apr 16, 2026, 4:30 PM EDT
Filing Type: 4
Importance Score:
9
Price at Filing: $1.06
Real-time Price: $0.790 info
Change: -$0.270 (-25%) info
Market Cap: $3.744M info
ALZN
Mar 20, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.83
Real-time Price: $0.790 info
Change: -$1.04 (-57%) info
Market Cap: $3.744M info
ALZN
Mar 16, 2026, 8:17 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $2.16
Real-time Price: $0.790 info
Change: -$1.37 (-63%) info
Market Cap: $3.744M info
ALZN
Mar 11, 2026, 7:51 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $2.23
Real-time Price: $0.790 info
Change: -$1.44 (-65%) info
Market Cap: $3.744M info
ALZN
Mar 06, 2026, 4:46 PM EST
Filing Type: 424B5
Importance Score:
9
Price at Filing: $1.98
Real-time Price: $0.790 info
Change: -$1.19 (-60%) info
Market Cap: $3.744M info
ALZN
Mar 06, 2026, 4:30 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.98
Real-time Price: $0.790 info
Change: -$1.19 (-60%) info
Market Cap: $3.744M info
ALZN
Feb 26, 2026, 5:12 PM EST
Filing Type: DEFA14A
Importance Score:
9
Price at Filing: $2.08
Real-time Price: $0.790 info
Change: -$1.29 (-62%) info
Market Cap: $3.744M info
ALZN
Feb 26, 2026, 5:12 PM EST
Filing Type: DEF 14A
Importance Score:
9
Price at Filing: $2.08
Real-time Price: $0.790 info
Change: -$1.29 (-62%) info
Market Cap: $3.744M info
ALZN
Feb 09, 2026, 4:30 PM EST
Filing Type: PRE 14A
Importance Score:
9
Price at Filing: $1.97
Real-time Price: $0.790 info
Change: -$1.18 (-60%) info
Market Cap: $3.744M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets